Despite reports that increased serum IL-17A represents a poor prognostic marker in AML, our findings may suggest an immuno-protective role of IL-17A in some cases, as described in other cancer types [66,67,68,69]. The gene discussed is IL17A; the disease is acute myeloid leukemia.